Evidence map›Paper›PMID 35064294›Full record

ReviewPsychopharmacology2022

Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.

Steven A Barker

Erratum issuedOpen access · bronzeAbstract readReview
In one paragraph

Review in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Science advances · 2025
    Article
  9. Addressing blinding in classic psychedelic studies with innovative active placebos.The international journal of neuropsychopharmacology · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Application of DeuteratedACS medicinal chemistry letters · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Steven A BarkerSchool of Veterinary Medicine, Department of Comparative Biomedical Sciences, Louisiana State University, Baton Rouge, LA, 70803, USA. Sbarke1@lsu.edu.
Louisiana State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As with all drugs, the route, form, and/or dose of a substance administered or applied can play a defining role in its overall pharmacology and use as a therapeutic. This review will focus on these factors as they relate to the psychedelic N,N-dimethyltryptamine (DMT). It will examine the positive and negative aspects of different formulations and routes of administration of DMT and the observed effects from such administrations in the form of ayahuasca teas; oral "pharmahuasca"; injections by intravenous (IV) and intramuscular (IM) routes; inhalation, insufflation; and other routes; and high-dose, low-dose, and "micro-dose" effects. The review will consider possible oral route of administration alternatives that would not require concomitant use of a monoamine oxidase inhibitor. The review will then address the current research findings for DMT from in vivo and in vitro studies as well as the possibility that these findings may be revealing the role of endogenous DMT in normal brain function.

Indexed as

BanisteriopsisHallucinogensAdministration, OralMonoamine Oxidase InhibitorsN,N-DimethyltryptamineHallucinogensMonoamine Oxidase InhibitorsN,N-DimethyltryptamineAyahuascaDeuterhuascaDimethyltryptamineMonoamine oxidase inhibitorPharmahuascaPsychedelic therapeuticsSigma-1 receptor

Identifiers

PMID35064294
PMCPMC8782705
OpenAlexW4207030820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.